FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR	OVAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* JONAS JEFFREY M													Persor	n(s) to Issu	ıer I	
JONAS JEFFREY M			2. Issuer Name and Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
		==0===== <u>peames</u> , <u>me.</u> [5.132]								X Direct		r	10% Owr		ner	
(Last) (First) (Middle)	3.	Date of Earliest Transaction (Month/Day/Year)								X	Officer below)			Other (spelow)	pecify	
C/O SAGE THERAPEUTICS, INC.	07	07/16/2019										President & CEO				
215 FIRST STREET																
213 PIKST STREET		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable							
(Street)	4.	4. If Americanient, Date of Original Flied (Month/Ddy/fedf)								Line)						
CAMBRIDGE MA 02142										X	X Form filed by One Reporting Person					
CHMBRIDGE WITH 02142											Form fi	led by More	than O	ne Report	ing	
(City) (State) (Zip)											Person	l				
Table I - Non-	Derivativ	re Sec	curit	ies Acc	uired, I	Disp	osed o	f, or Be	nefic	ially	Owned					
1. Title of Security (Instr. 3)	2. Transactio		2A. De		3.			ties Acquir			5. Amou		6. Owne		. Nature	
	Date Month/Day/Y			tion Date,	Code (Instr. 5)			osed Of (D) (Instr. 3, 4		4 and Securitie Benefici					of Indirect Beneficial	
	,		(Month/Day/Year)								ollowing (i) (I		nstr. 4)	Ownership (Instr. 4)		
					Code	v	Amount	t (A) or (D)		ice	Transact (Instr. 3 a	tion(s)		'		
Common Stock	07/16/20	/2019		М		27,000 A S		\$	0.45	39,115		Ι)			
Table II - D	erivative .g., puts,										wned					
		, cans	_													
1. Title of Derivative Security 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)	ate, Transaction Code (Instr				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	. Price of Perivative Security Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y O Fo O (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
									Amo	unt						
					Doto	_	vniration		Num	ber						
	Code	v	(A)		Date Exercisabl		xpiration ate	Title	of Share	es						
Stock Option (Right to \$0.45 07/16/2019	М			27,000	(1)	0	8/12/2023	Common Stock	27,0	000	\$0.00	64,987		D		

Explanation of Responses:

1. The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2011 Stock Option and Incentive Plan. The option fully vested on August 12, 2017.

Remarks:

/s/ Anne Marie Cook, as Attorney-in-Fact for Jeffrey M. 07/17/2019 **Jonas**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.